Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PIRS
Previous Symbol
CUSIPN/A
Phone857-246-8998
Debt
Debt-to-Equity RatioN/A
Current Ratio3.62
Quick Ratio3.62
Price-To-Earnings
Trailing P/E Ratio-7.30
Forward P/E Ratio-6.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.27 million
Price / Sales6.26
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.26 per share
Price / Book11.23
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-17,640,000.00
Net Margins-17.90%
Return on Equity-18.07%
Return on Assets-5.13%
Miscellaneous
Employees68
Outstanding Shares54,150,000
Market Cap$158.12 million
OptionableOptionable
Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions
What is Pieris Pharmaceuticals' stock symbol?
Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."
How were Pieris Pharmaceuticals' earnings last quarter?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.16 million. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. View Pieris Pharmaceuticals' Earnings History.
When is Pieris Pharmaceuticals' next earnings date?
What price target have analysts set for PIRS?
5 brokers have issued 1-year target prices for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $13.00. On average, they expect Pieris Pharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 242.5% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.
What is the consensus analysts' recommendation for Pieris Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.
Has Pieris Pharmaceuticals been receiving favorable news coverage?
Press coverage about PIRS stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Are investors shorting Pieris Pharmaceuticals?
Pieris Pharmaceuticals saw a decline in short interest in November. As of November 30th, there was short interest totalling 2,175,954 shares, a decline of 26.4% from the November 15th total of 2,955,342 shares. Based on an average daily volume of 663,778 shares, the days-to-cover ratio is currently 3.3 days. Currently, 4.1% of the shares of the stock are sold short. View Pieris Pharmaceuticals' Current Options Chain.
Who are some of Pieris Pharmaceuticals' key competitors?
Some companies that are related to Pieris Pharmaceuticals include Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM), Geovax Labs (GOVX), ALGAE TEC LTD/S (ALGXY), Protalex (PRTX) and Tenax Therapeutics (TENX).
Who are Pieris Pharmaceuticals' key executives?
Pieris Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen S. Yoder, CEO, Pres & Director (Age 42)
- Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 43)
- Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 67)
- Mr. Claus Schalper, Co-Founder & Sr. Advisor
- Maria Kelman, Director of Investor Relations
Who are Pieris Pharmaceuticals' major shareholders?
Pieris Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (4.01%), Prosight Management LP (3.07%), Renaissance Technologies LLC (2.56%), Sphera Funds Management LTD. (1.67%), Lombard Odier Asset Management USA Corp (0.75%) and Vanguard Group Inc. (0.68%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Christopher P Kiritsy, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.
Which institutional investors are selling Pieris Pharmaceuticals stock?
PIRS stock was sold by a variety of institutional investors in the last quarter, including Lombard Odier Asset Management USA Corp, Renaissance Technologies LLC, First Quadrant L P CA, AQR Capital Management LLC, Virtus ETF Advisers LLC, Assenagon Asset Management S.A. and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Pieris Pharmaceuticals.
Which institutional investors are buying Pieris Pharmaceuticals stock?
PIRS stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, P.A.W. Capital Corp, Marshall Wace LLP, Citadel Advisors LLC, GSA Capital Partners LLP, Platinum Investment Management Ltd., Massachusetts Financial Services Co. MA and Sphera Funds Management LTD.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Christopher P Kiritsy and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.
How do I buy shares of Pieris Pharmaceuticals?
Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pieris Pharmaceuticals' stock price today?
One share of PIRS stock can currently be purchased for approximately $2.92.
How big of a company is Pieris Pharmaceuticals?
Pieris Pharmaceuticals has a market capitalization of $158.12 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.
What is Pieris Pharmaceuticals' official website?
How can I contact Pieris Pharmaceuticals?
Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]
MarketBeat Community Rating for Pieris Pharmaceuticals (NASDAQ PIRS)
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
